Drugs in Dev. Immunology
IND Enabling
Australia 
Lead Product(s) : IMP761
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Immutep Receives Clearance for Phase I Study of LAG-3 Agonist Antibody
Details : IMP761 is the world’s first therapeutic LAG-3 agonist antibody, which is being evaluated i the early-stage clinical rial studies for the treatment of autoimmune diseases.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 17, 2024
Lead Product(s) : IMP761
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMP761
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMP761 is a first-in-class immunosuppressive agonist antibody to LAG-3. As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 06, 2022
Lead Product(s) : IMP761
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IHL-675A is a combination cannabinoid drug comprising cannabidiol ('CBD') and hydroxychloroquine ('HCQ') in a fixed dose combination,synergistically to inhibit production of key inflammatory cytokines.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : Cannabidiol,Hydroxychloroquine Sulphate
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CYP-001
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
Details : CYP-001 (mesenchymoangioblast-derived mesenchymal stem cells) met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : CYP-001
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
